Global Registrational Strategy for SYN-2510/IMM2510

文章预览

Global registrational strategy in first-line non-squamous and squamous non-small cell lung cancer (NSCLC) Global registrational strategy in first-line triple-negative breast cancer (TNBC) Initiation of Phase 1b/2 IMM2510/SYN-2510 + chemotherapy combination in first-line NSCLC anticipated in late 2024 in China Initiation of Phase 1b/2 IMM2510/SYN-2510 + chemotherapy combination in first-line TNBC  anticipated in early 2025 in China US IND submission for SYN-2510 targeted in late 2024, starting with Phase 2 trial of SYN-2510 monotherapy in second-line NSCLC Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510 Dallas, Texas, and Shanghai, China, Sep. 16, 2024 – Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX:1541, “ImmuneOnco”) announced today the global registrational strategy for the PD-L1xVEGF bispecific antibody SYN-2510/IMM2510 in combination with chemotherapy in front-line non-small cell lung canc ………………………………